All In Biotech

Drug Trial Radar · NCT05822752

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

130

Actual

Start

Sep 21, 2023

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), lenvatinib, or sorafenib. Approximately 120 adult participants will be enrolled in the study across 60 sites worldwide. In arm 1 (control), participants will receive the investigator's choice: lenvatinib as an oral capsule or sorafenib as an oral tablet, once daily. In arm 2, participants will receive intravenously (IV) infused livmoniplimab (dose A) in combination with IV infused budigalimab, every 3 weeks. In arm 3, participants will receive intravenously (IV) infused livmoniplimab (dose B) in combination with IV infused budigalimab, every 3 weeks. The estimated duration of the study is up to 2 years There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • BudigalimabDrug

    Intravenous (IV) Infusion

  • LivmoniplimabDrug

    Intravenous (IV) Infusion

  • LenvatinibDrug

    Oral: Capsule

  • SorafenibDrug

    Oral: Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response (BOR) per InvestigatorTime frame: Through Study Completion, Up to Approximately 27 Months

Locations

59 sites in 7 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313

    Prescott Valley, Arizona

  • Highlands Oncology Group, PA /ID# 253158

    Springdale, Arkansas

  • University of California, Los Angeles /ID# 253292

    Los Angeles, California

  • UC Irvine /ID# 252707

    Orange, California

  • California Pacific Medical Center - San Francisco - Webster Street /ID# 253291

    San Francisco, California

  • Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163

    Denver, Colorado

  • AdventHealth Orlando /ID# 252865

    Orlando, Florida

  • The University of Chicago Medical Center /ID# 252870

    Chicago, Illinois

  • Hematology/Oncology Clinic /ID# 253851

    Baton Rouge, Louisiana

  • Dana-Farber Cancer Institute /ID# 252696

    Boston, Massachusetts

  • Henry Ford Hospital /ID# 253342

    Detroit, Michigan

  • Washington University-School of Medicine /ID# 252698

    St Louis, Missouri

  • NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708

    New York, New York

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252705

    New York, New York

  • Messino Cancer Center - Asheville /ID# 253888

    Asheville, North Carolina

  • University of North Carolina /ID# 252739

    Chapel Hill, North Carolina

  • Lifespan Cancer Institute at Rhode Island Hospital /ID# 252699

    Providence, Rhode Island

  • Duplicate_Texas Oncology - Medical City Dallas /ID# 254164

    Dallas, Texas

  • Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 252770

    Dallas, Texas

  • Texas Oncology - Northeast Texas /ID# 254184

    Tyler, Texas

  • AP-HP - Hopital Paul-Brousse /ID# 253646

    Villejuif, France

  • Centre Hospitalier Universitaire de Bordeaux /ID# 252749

    Pessac, Gironde, France

  • CHU Montpellier - Hopital Saint Eloi /ID# 252760

    Montpellier, Herault, France

  • Hopital Beaujon /ID# 252758

    Clichy, Île-de-France Region, France

  • CHU Grenoble - Hopital Michallon /ID# 252755

    La Tronche, Isere, France

  • CHRU Lille - Hopital Claude Huriez /ID# 252748

    Lille, Nord, France

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 253247

    Bologna, Italy

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 253142

    Palermo, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 253141

    Roma, Italy

  • Azienda Ospedaliero Universitaria Careggi /ID# 254444

    Florence, Firenze, Italy

  • IRCCS Ospedale San Raffaele /ID# 252910

    Milan, Milano, Italy

  • P.O. Ospedale del Mare /ID# 253140

    Naples, Napoli, Italy

  • Chiba University Hospital /ID# 255190

    Chiba, Chiba, Japan

  • National Cancer Center Hospital East /ID# 253419

    Kashiwa-shi, Chiba, Japan

  • Kanazawa University Hospital /ID# 254861

    Kanazawa, Ishikawa-ken, Japan

  • Yokohama City University Medical Center /ID# 255790

    Yokohama, Kanagawa, Japan

  • Kindai University Hospital /ID# 255106

    Osakasayama-shi, Osaka, Japan

  • CHA Bundang Medical Center /ID# 253054

    Seongnam, Gyeonggido, South Korea

  • Seoul National University Bundang Hospital /ID# 253412

    Seongnam-si, Gyeonggido, South Korea

  • Chonnam National University Hwasun Hospital /ID# 253133

    Hwasun-gun, Jeonranamdo, South Korea

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.